Mild haemophilia: A disease with many faces and many unexpected pitfalls

Haemophilia

Volumn 16, Issue SUPPL. 5, 2010, Pages 100-106

  Peerlinck, K ^a   Jacquemin, M ^b  

^a Hemophilia Center   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DESMOPRESSIN; IMMUNOGLOBULIN G; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RITUXIMAB;

ARTICLE; BLEEDING; BLOOD PRESSURE; CONTINUOUS INFUSION; CROSS REACTION; DELAYED DIAGNOSIS; DRUG INDUCED HEADACHE; DRUG MEGADOSE; FLUSHING; HEART RATE; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HYPONATREMIA; LIFE EXPECTANCY; LOW DRUG DOSE; MISSENSE MUTATION; MOLECULAR MECHANICS; MORBIDITY; MUCOSAL BLEEDING; PARTIAL THROMBOPLASTIN TIME; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT; TACHYPHYLAXIS; THROMBOSIS; TREATMENT RESPONSE;

BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; DEAMINO ARGININE VASOPRESSIN; HEMOPHILIA A; HEMOSTATICS; HUMANS;

EID: 77955018016     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02306.x     Document Type: Article

References (51)

1. Stonebraker JS, Bolton-Maggs PH, Michael Soucie J, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2009
2. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy - global progress towards optimal care. Haemophilia 2006, 12:75-81.
3. Aznar JA, Abad-Franch L, Cortina VR, Marco P. The national registry of haemophilia A and B in Spain: results from a census of patients. Haemophilia 2009, 15:1327-30.
4. Poon MC, Luke KH. Haemophilia care in China: achievements of a decade of World Federation of Hemophilia treatment centre twinning activities. Haemophilia 2008, 14:879-88.
5. Darby SC, Kan SW, Spooner RJ. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007, 110:815-25.
6. Chambost H, Gaboulaud V, Coatmelec B, Rafowicz A, Schneider P, Calvez T. What factors influence the age at diagnosis of hemophilia? Results of the French hemophilia cohort. J Pediatr 2002, 141:548-52.
7. Plug I, Mauser-Bunschoten EP, Brocker-Vriends AH. Bleeding in carriers of hemophilia. Blood 2006, 108:52-6.
8. Miesbach W, Alesci S, Krekeler S, Seifried E. Age-dependent increase of FVIII:C in mild haemophilia A. Haemophilia 2009, 15:1022-6.
9. Parquet-Gernez A, Mazurier C, Goudemand M. Functional and immunological assays of FVIII in 133 haemophiliacs - characterization of a subgroup of patients with mild haemophilia A and discrepancy in 1- and 2-stage assays. Thromb Haemost 1988, 59:202-6.
10. Duncan EM, Duncan BM, Tunbridge LJ, Lloyd JV. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br J Haematol 1994, 87:846-8.
11. Poulsen AL, Pedersen LH, Hvas AM, Poulsen LH, Thykjaer H, Ingerslev J. Assay discrepancy in mild haemophilia A: entire population study in a National Haemophilia Centre. Haemophilia 2009, 15:285-9.
12. Gilmore R, Harmon S, Gannon C, Byrne M, O'Donnell JS, Jenkins PV. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy. Haemophilia 2010
13. Pipe SW, Eickhorst AN, McKinley SH, Saenko EL, Kaufman RJ. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood 1999, 93:176-83.
14. Pipe SW, Saenko EL, Eickhorst AN, Kemball-Cook G, Kaufman RJ. Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood 2001, 97:685-91.
15. Trossaert M, Regnault V, Sigaud M, Boisseau P, Fressinaud E, Lecompte T. Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype. J Thromb Haemost 2008, 6:486-93.
16. d'Oiron R, Pipe SW, Jacquemin M. Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development. Haemophilia 2008, 14(Suppl. 3):138-46.
17. Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998, 4:558-63.
18. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia 2000, 6(Suppl. 1):60-7.
19. Lethagen S. Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety. Semin Thromb Hemost 2003, 29:101-6.
20. Castaman G, Mancuso ME, Giacomelli SH. Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A. J Thromb Haemost 2009, 7:1824-31.
21. Nolan B, White B, Smith J, O'Reily C, Fitzpatrick B, Smith OP. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders. Br J Haematol 2000, 109:865-9.
22. Mannucci PM, Vicente V, Alberca I. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses. Thromb Haemost 1987, 58:1037-9.
23. Mannucci PM. Hemostatic drugs. N Engl J Med 1998, 339:245-53.
24. Eckhardt CL, Menke LA, van Ommen CH. Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost 2009, 7:930-7.
25. Hay CR, Ludlam CA, Colvin BT. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998, 79:762-6.
26. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993, 328:453-9.
27. Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group. Thromb Haemost 1992, 67:600-2.
28. Rizza CR, Spooner RJ. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom. Br Med J (Clin Res Ed) 1983, 286:929-33.
29. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988, 71:344-8.
30. Rizza CR, Spooner RJ, Giangrande PL. Treatment of haemophilia in the United Kingdom 1981-1996. Haemophilia 2001, 7:349-59.
31. Fijnvandraat K, Turenhout EA, van den Brink EN. The missense mutation Arg593 --> Cys is related to antibody formation in a patient with mild hemophilia A. Blood 1997, 89:4371-7.
32. Vlot AJ, Wittebol S, Strengers PF. Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618-->Ser mutation responsive to immune tolerance induction and cyclophosphamide. Br J Haematol 2002, 117:136-40.
33. Santagostino E, Gringeri A, Tagliavacca L, Mannucci PM. Inhibitors to factor VIII in a family with mild hemophilia: molecular characterization and response to factor VIII and desmopressin. Thromb Haemost 1995, 74:619-21.
34. Peerlinck K, Jacquemin MG, Arnout J. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood 1999, 93:2267-73.
35. Kesteven PJ, Holland LJ, Lawrie AS, Savidge GF. Inhibitor to factor VIII in mild haemophilia. Thromb Haemost 1984, 52:50-2.
36. Sharathkumar A, Lillicrap D, Blanchette VS. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003, 1:1228-36.
37. Thompson AR, Murphy ME, Liu M. Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation. Blood 1997, 90:1902-10.
38. Knobe KE, Villoutreix BO, Tengborn LI, Petrini P, Ljung RC. Factor VIII inhibitors in two families with mild haemophilia A: structural analysis of the mutations. Haemostasis 2000, 30:268-79.
39. Franchini M, Girelli D, Olivieri O. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A. Haemophilia 2006, 12:448-51.
40. Jacquemin M, Benhida A, Peerlinck K. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood 2000, 95:156-63.
41. Suzuki H, Shima M, Arai M. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes. Thromb Haemost 1997, 77:862-7.
42. d'Oiron R, Lavergne JM, Lavend'homme R. Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development. Blood 2004, 103:155-7.
43. Gilles JG, Lavend'homme R, Peerlinck K. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes. Thromb Haemost 1999, 82:40-5.
44. Jacquemin M, De Maeyer M, D'Oiron R, Lavend'Homme R, Peerlinck K, Saint-Remy JM. Molecular mechanisms of mild and moderate hemophilia A. J Thromb Haemost 2003, 1:456-63.
45. James EA, Kwok WW, Ettinger RA, Thompson AR, Pratt KP. T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide. J Thromb Haemost 2007, 5:2399-407.
46. White B, Cotter M, Byrne M, O'Shea E, Smith OP. High responding factor VIII inhibitors in mild haemophilia - is there a link with recent changes in clinical practice? Haemophilia 2000, 6:113-5.
47. Carcao M, St Louis J, Poon MC. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006, 12:7-18.
48. Dunkley S, Kershaw G, Young G. Rituximab treatment of mild haemophilia A with inhibitors: a proposed treatment protocol. Haemophilia 2006, 12:663-7.
49. Robbins D, Kulkarni R, Gera R, Scott-Emuakpor AB, Bosma K, Penner JA. Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy. Am J Hematol 2001, 68:184-8.
50. d'Oiron R, Volot F, Reynaud J. Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors. Semin Hematol 2006, 43:S3-9.
51. Franchini M, Mengoli C, Lippi G. Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis. Haemophilia 2008, 14:903-12.